ACRV

$0.00

(

0.00%

)
Quote details

stock

Acrivon Therapeutics, Inc. Common Stock

NASDAQ | ACRV

1.35

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Aug 15, 2025)

$42M

MARKET CAP

-

P/E Ratio

-2.24

EPS

$10

52 Week High

$1.1

52 Week Low

LIFE SCIENCES

Sector

ACRV Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

ACRV Technicals

Tags:

ACRV Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $1M
Costof Goods And Services Sold $1M
Operating Income -$89M
Selling General And Administrative $25M
Research And Development $63M
Operating Expenses $89M
Investment Income Net -
Net Interest Income $9.2M
Interest Income $9.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$81M
Comprehensive Income Net Of Tax -
Ebit -$81M
Ebitda -$80M
Net Income -$81M

Revenue & Profitability

Earnings Performance

ACRV Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $197M
Total Current Assets $182M
Cash And Cash Equivalents At Carrying Value $40M
Cash And Short Term Investments $40M
Inventory -
Current Net Receivables -
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $5.1M
Short Term Investments $140M
Other Current Assets $2.1M
Other Non Current Assets -
Total Liabilities $20M
Total Current Liabilities $17M
Current Accounts Payable $758K
Deferred Revenue -
Current Debt -
Short Term Debt $1.1M
Total Non Current Liabilities $2.6M
Capital Lease Obligations $3.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.6M
Other Current Liabilities $11M
Other Non Current Liabilities -
Total Shareholder Equity $177M
Treasury Stock -
Retained Earnings -$197M
Common Stock $31K
Common Stock Shares Outstanding $338M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$66M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1M
Capital Expenditures $2.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$52M
Cashflow From Financing $121M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$81M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $1M
Costof Goods And Services Sold $1M
Operating Income -$89M
Selling General And Administrative $25M
Research And Development $63M
Operating Expenses $89M
Investment Income Net -
Net Interest Income $9.2M
Interest Income $9.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1M
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$81M
Comprehensive Income Net Of Tax -
Ebit -$81M
Ebitda -$80M
Net Income -$81M

ACRV News

ACRV Profile

Acrivon Therapeutics, Inc. Common Stock Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.

Discover more tools and features to empower your trading
Explore Features

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.